Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ikena Oncology Inc (NQ: IKNA )

1.700 -0.020 (-1.16%)
Streaming Delayed Price Updated: 1:58 PM EDT, Sep 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ikena Oncology Inc

< Previous 1 2 Next >
Ikena Oncology Reports Second Quarter 2024 Financial Results
Strong financial position with $145 million in cash and investments at close of second quarter 
From Ikena Oncology, Inc.
Via GlobeNewswire
UPDATE – Ikena Oncology Announces Strategic Update
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Announces Strategic Update
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Present at Multiple November 2023 Investor Conferences
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Participate in September 2023 Investor Conferences
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Participate in Upcoming Investor Conferences
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Announces $40 Million Underwritten Offering
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Appoints Owen Hughes as Board Chair
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma
From Ikena Oncology, Inc.
Via GlobeNewswire
UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
From Ikena Oncology, Inc.
Via GlobeNewswire
Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance
From Ikena Oncology, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.